Carrick Therapeutics Announces First Patient Dosed in Phase 1b/2 Clinical Trial of Samuraciclib in Combination with Vepdegestrant in Patients with Advanced Breast Cancer
14 févr. 2024 08h00 HE
|
CARRICK THERAPEUTICS LIMITED
BOSTON, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today announced that the...
Carrick Therapeutics Announces First Patient Dosed in Phase 2b Clinical Trial of Samuraciclib in Combination with Fulvestrant in Patients with Advanced HR+, HER2- Breast Cancer
15 déc. 2023 08h00 HE
|
CARRICK THERAPEUTICS LIMITED
BOSTON, Dec. 15, 2023 (GLOBE NEWSWIRE) -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today announced that the...
Carrick Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of Samuraciclib in Combination with Elacestrant in Patients with Advanced Breast Cancer
18 oct. 2023 09h00 HE
|
CARRICK THERAPEUTICS LIMITED; The Menarini Group
BOSTON, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today announced that the...
Carrick Therapeutics Announces U.S. FDA Clearance of IND for CT7439, a First-In-Class Inhibitor of CDK12/13
07 sept. 2023 08h00 HE
|
CARRICK THERAPEUTICS LIMITED
DUBLIN, Ireland and BOSTON, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today...
Carrick Therapeutics Announces Clinical Trial Collaboration with Arvinas and Pfizer to Evaluate Samuraciclib and Vepdegestrant Combination
06 juil. 2023 09h00 HE
|
CARRICK THERAPEUTICS LIMITED
DUBLIN, Ireland and BOSTON, July 06, 2023 (GLOBE NEWSWIRE) -- Carrick Therapeutics, an oncology-focused biopharmaceutical company discovering and developing highly differentiated therapies, today...
Carrick Therapeutics Closes Series C Financing
01 déc. 2022 08h05 HE
|
CARRICK THERAPEUTICS LIMITED
Raised $25 million from a Series C financing Proceeds to advance development of first-in-class oncology pipeline across multiple indications DUBLIN, Ireland and BOSTON, Dec. 01, 2022 (GLOBE...
Carrick Therapeutics Announces $35 Million Investment from Pfizer
01 déc. 2022 08h00 HE
|
CARRICK THERAPEUTICS LIMITED
Funding supports advancement of samuraciclib, an oral CDK7 inhibitor, in combination with endocrine therapy for HR+, HER2- advanced breast cancer Adam Schayowitz, Ph.D., Vice President and...